# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0001193125-26-096771
**Filing Date:** 2026-3
**Character Count:** 24759
**Document Hash:** a33144d08f171edb664861f73fbc49a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-096771.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001193125-26-096771

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**EFFECTIVENESS DATE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294105
- **FILM NUMBER:** 26731821

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103

**As filed with the Securities and Exchange Commission on March 6, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Jade Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Nevada** | **83-1377888** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**Jade Biosciences, Inc.** 

**221 Crescent St., Building 23, Suite 105** 

**Waltham, MA 02453** 

**(Address of Principal Executive Offices, Zip Code)** 

**Jade Biosciences, Inc. 2025 Stock Incentive Plan** 

**Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan** 

**(Full title of the plans)** 

**Elizabeth Balta** 

**Chief Legal Officer and Corporate Secretary** 

**Jade Biosciences, Inc.** 

**221 Crescent St., Building 23, Suite 105** 

**Waltham, MA 02453** 

**(781) 312-3013**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***With a copy to:***

**Cheston J. Larson** 

**Matthew T. Bush** 

**Anthony A. Gostanian** 

**Latham & Watkins LLP** 

**12670 High Bluff Drive** 

**San Diego, California 92130** 

**(858) 523-5400** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

------

**EXPLANATORY NOTE** 

This Registration Statement registers the offer and sale of an additional 3,535,788 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Jade Biosciences, Inc., a Nevada corporation (the "Registrant"), for issuance under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), as well as the offer and sale of an additional 707,157 shares of Common Stock for issuance under the Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan (the "ESPP"). In accordance with Instruction E to Form S-8, the contents of the prior Registration Statement on Form S-8 (File No. 333-288425), previously filed with the Securities and Exchange Commission (the "Commission") on June 30, 2025 with respect to the 2025 Plan and the ESPP, are hereby incorporated by reference herein.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

**Item 1. Plan Information.** 

The documents containing the information specified in Part I of Form S-8 will be delivered to the grantee as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The Commission allows us to "incorporate by reference" certain information we file with them, which means that we can disclose important information to you by referring you to those documents. The following documents, which have previously been filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated by reference herein and shall be deemed to be a part hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1798749/000119312526096550/ck0001798749-20251231.htm) for the year ended December 31, 2025, filed with the Commission on March 6, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the description of the Common Stock contained in the Registrant's Registration Statement on [Form 8-A/A](http://www.sec.gov/Archives/edgar/data/1798749/000119312525179868/d89363d8a12ba.htm) (File No. 001-40544), filed with the Commission on August 
13, 2025, as updated by the Description of Registered Securities filed as [Exhibit 4.4](http://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-ex4_4.htm) to the Registrant's Annual Report on Form 10-K, filed with the Commission on March 6, 2026, together with any amendment or report filed with the Commission for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant has disclosed or discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it has furnished or may from time to time furnish to the Commission is or will be incorporated by reference into, or otherwise included in, this Registration Statement.

------

Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Exhibit Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.4 of the Registrant's Current Report on Form 8-K, filed with the Commission on May 1, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525110004/d847557dex34.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Bylaws of the Registrant (incorporated by reference to Exhibit 3.5 of the Registrant's Current Report on Form 8-K, filed with the Commission on May 1, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525110004/d847557dex35.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Brownstein Hyatt Farber Schreck, LLP.](d106310dex51.htm) |
| 23.1\* | [Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.](d106310dex231.htm) |
| 23.2\* | [Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.1).](d106310dex51.htm) |
| 24.1\* | [Power of Attorney (included on the signature page to this Registration Statement).](#tx106310_1) |
| 99.1 | [Jade Biosciences, Inc. 2025 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 of the Registrant's Current Report on Form 8-K, filed with the Commission on May 1, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525110004/d847557dex1010.htm) |
| 99.2 | [Form of Grant Notice for Stock Option and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (Directors) (incorporated by reference to Exhibit 99.2 to the Registrant's Form S-8, filed with the Commission on June 30, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525152722/d242652dex992.htm) |
| 99.3 | [Form of Grant Notice for Stock Option and Standard Terms and Conditions for Stock Options under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (Employees) (incorporated by reference to Exhibit 99.3 to the Registrant's Form S-8, filed with the Commission on June 30, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525152722/d242652dex993.htm) |
| 99.4 | [Form of Grant Notice for Restricted Stock Units and Standard Terms and Conditions for Restricted Stock Units under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the Registrant's Form 10-K, filed with the Commission on March 6, 2026).](http://www.sec.gov/Archives/edgar/data/1798749/000119312526096550/ck0001798749-ex10_14.htm) |
| 99.5 | [Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 of the Registrant's Current Report on Form 8-K, filed with the Commission on May 1, 2025).](http://www.sec.gov/Archives/edgar/data/1798749/000119312525110004/d847557dex1011.htm) |
| 107.1\* | [Filing Fee Table.](d106310dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Waltham, Commonwealth of Massachusetts, on the 6th day of March 2026.

---

| | |
|:---|:---|
| **JADE BIOSCIENCES, INC.** | **JADE BIOSCIENCES, INC.** |
| By: | /s/ Bradford Dahms |
| Name: | Bradford Dahms |
| Title: | Chief Financial Officer and Treasurer |

---

------

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Tom Frohlich, Bradford Dahms and Elizabeth Balta and each of them (with full power to each of them to act alone), the individual's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Tom Frohlich<br> Tom Frohlich | Chief Executive Officer and Director<br> (*principal executive officer*) | March 6, 2026 |
| /s/ Bradford Dahms<br> Bradford Dahms | Chief Financial Officer and Treasurer<br> (*principal financial and accounting officer*) | March 6, 2026 |
| /s/ Eric Dobmeier<br> Eric Dobmeier, J.D. | Chair of the Board | March 6, 2026 |
| /s/ Chris Cain<br> Chris Cain, Ph.D. | Director | March 6, 2026 |
| /s/ Tomas Kiselak<br> Tomas Kiselak | Director | March 6, 2026 |
| /s/ Lawrence Klein<br> Lawrence Klein, Ph.D. | Director | March 6, 2026 |
| /s/ Erin Lavelle<br> Erin Lavelle | Director | March 6, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g106310g0306061905666.jpg) | **Brownstein Hyatt Farber Schreck, LLP**<br>702.382.2101 main<br> 100 North City Parkway, Suite 1600<br> Las Vegas, Nevada 89106 |

---

March 6, 2026

Jade Biosciences, Inc.

221 Crescent St., Building 23, Suite 105

Waltham, MA 02453

To the addressee set forth above:

We have acted as local Nevada counsel to Jade Biosciences, Inc., a Nevada corporation (the "<u>Company</u>"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Act</u>"), relating to the registration of an additional (i) 3,535,788 shares (the "<u>2025 Plan Shares</u>") of the Company's common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), issuable under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (the "<u>2025 Plan</u>") and (ii) 707,157 shares of Common Stock (the "<u>ESPP Shares</u>" and, together with the 2025 Plan Shares, the "<u>Shares</u>"), issuable under the Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan (the "<u>ESPP</u>" and together with the 2025 Plan, the "<u>Plans</u>"). This opinion letter is being delivered at your request, pursuant to the requirements of Item 601(b)(5) of Regulation S-K under the Act.

In our capacity as such counsel, we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization and issuance of the Shares as contemplated by the Plans and as described in the Registration Statement. For purposes of this opinion letter, and except to the extent set forth in the opinion expressed below, we have assumed that all such proceedings have been or will be timely completed in the manner contemplated by each of the Plans, and as presently proposed in the Registration Statement.

For purposes of issuing the opinion hereinafter expressed, we have (a) made such legal and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified to our satisfaction as being true copies of (i) the Registration Statement, (ii) the Plans, (iii) the Company's articles of incorporation and bylaws, each as amended to date, and (iv) such other agreements, instruments, corporate records (including resolutions of the board of directors and any committee thereof and of the stockholders of the Company) and other documents, or forms thereof, as we have deemed necessary or appropriate, and (b) obtained from officers and other representatives and agents of the Company and from public officials, and have relied upon, such certificates, representations, assurances and public filings as we have deemed necessary or appropriate.

Without limiting the generality of the foregoing, we have, with your permission, assumed without independent verification that (i) the Plans are valid, binding and enforceable obligations of the Company; (ii) each natural person executing a document has or will have sufficient legal capacity to do so; (iii) all documents submitted to us as originals are authentic, the signatures on all documents we reviewed are genuine and all documents submitted to us as certified, conformed, photostatic, electronic or facsimile

**www.bhfs.com** 

------

Jade Biosciences, Inc.

March 6, 2026

copies conform to the original document; (iv) except to the extent set forth in the opinion paragraph below, the statements of fact and representations and warranties set forth in the documents we have reviewed, including the Plans, are or will at all relevant times be, true and correct as to factual matters; (v) all corporate records made available to us by the Company, and all public records we have reviewed, are accurate and complete; (vi) prior to the conversion of Jade Biosciences, Inc., a Delaware corporation, into a Nevada corporation, the Company took all corporate action required under the laws of the State of Delaware to authorize and approve the Plans and the performance by the Company of its obligations thereunder, including the issuance of the Shares; and (vii) after the issuance of any Shares, the total number of issued and outstanding shares of Common Stock, together with the total number of shares of Common Stock then reserved for issuance or obligated to be issued by the Company pursuant to any agreement, plan or arrangement, including any of the Plans, or otherwise, will not exceed the total number of shares of Common Stock then authorized under the Company's articles of incorporation.

We are qualified to practice law in the State of Nevada. The opinion set forth herein is expressly limited to, and based exclusively on, the general corporate laws of the State of Nevada, and we do not purport to be experts on, or to express any opinion with respect to the applicability thereto or the effect thereon of, the laws of any other jurisdiction. We express no opinion concerning, and we assume no responsibility as to laws or judicial decisions related to, or any orders, consents or other authorizations or approvals as may be required by, any federal laws, rules or regulations, including, without limitation, any federal securities laws, rules or regulations, or any state securities or "blue sky" laws, rules or regulations.

Based on the foregoing and in reliance thereon, and having regard to legal considerations and other information that we deem relevant, we are of the opinion that the Shares have been duly authorized by the Company and, if, when and to the extent issued in accordance with all applicable terms and conditions set forth in the relevant Plan and in exchange for the consideration required thereunder, and as described in the Registration Statement, the Shares will be validly issued, fully paid and non-assessable.

The opinion expressed herein is based upon the applicable laws of the State of Nevada and the facts in existence on the date of this opinion letter. In delivering this opinion letter to you, we disclaim any obligation to update or supplement the opinion set forth herein or to apprise you of any changes in any laws or facts after such time as the Registration Statement is declared effective. No opinion is offered or implied as to any matter, and no inference may be drawn, beyond the strict scope of the specific issues expressly addressed by the opinion set forth herein.

We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Brownstein Hyatt Farber Schreck, LLP

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Jade Biosciences, Inc. of our report dated March 6, 2026 relating to the financial statements, which appears in Jade Biosciences, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

---

| |
|:---|
| /s/ PricewaterhouseCoopers LLP |
| Boston, Massachusetts |
| March 6, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Jade Biosciences, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share | Other | 3535788 | $13.825 | $48882269.10 | 0.0001381 | $6750.65 |
| 2 | Equity | Common stock, $0.0001 par value per share | Other | 707157 | $13.825 | $9776445.53 | 0.0001381 | $1350.13 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $58658714.63  |  | $8100.78  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $8100.78  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 (this "Registration Statement") shall also cover any additional shares of common stock, par value $0.0001 per share (the "Common Stock") of Jade Biosciences, Inc. (the "Registrant") that become issuable under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (the "2025 Plan") and the Jade Biosciences, Inc. 2025 Employee Stock Purchase Plan (the "ESPP") to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions. In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement also covers an indeterminate amount of interests to be offered or sold pursuant to the 2025 Plan and the ESPP. (2) Represents 3,535,788 shares of Common Stock available for future issuance (or that may become available for issuance) under the 2025 Plan. (3) Proposed maximum offering price per unit estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Capital Market, on March 5, 2026, which date is within five business days prior to filing this Registration Statement.

<sup>2</sup> (1) Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the 2025 Plan and the ESPP to prevent dilution resulting from stock splits, stock dividends, recapitalizations or similar transactions. In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement also covers an indeterminate amount of interests to be offered or sold pursuant to the 2025 Plan and the ESPP. (2) Represents 707,157 shares of Common Stock available for future issuance (or that may become available for issuance) under the ESPP. (3) Proposed maximum offering price per unit estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Capital Market, on March 5, 2026, which date is within five business days prior to filing this Registration Statement.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---